Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 08:59
04/08/21
04/08
08:59
04/08/21
08:59
ORBC

Orbcomm

$7.58 /

-0.24 (-3.07%)

, IMMP

Immutep

$3.20 /

+0.17 (+5.61%)

, GME

GameStop

$177.95 /

-6.24 (-3.39%)

, AVCT

AVCtechnologies

$5.81 /

-0.25 (-4.13%)

, CAG

Conagra Brands

$37.24 /

-0.365 (-0.97%)

, APOG

Apogee Enterprises

$39.50 /

-1.11 (-2.73%)

, VLO

Valero

$74.45 /

+0.3 (+0.40%)

, BOX

Box

$24.26 /

+0.15 (+0.62%)

, OTIC

Otonomy

$2.46 /

-0.11 (-4.28%)

, AMRS

Amyris

$16.87 /

-1.37 (-7.51%)

, CGC

Canopy Growth

$29.92 /

-0.97 (-3.14%)

Check out this morning's…

ShowHide Related Items >><<
VLO Valero
$74.45 /

+0.3 (+0.40%)

OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

ORBC Orbcomm
$7.58 /

-0.24 (-3.07%)

IMMP Immutep
$3.20 /

+0.17 (+5.61%)

GME GameStop
$177.95 /

-6.24 (-3.39%)

CGC Canopy Growth
$29.92 /

-0.97 (-3.14%)

CAG Conagra Brands
$37.24 /

-0.365 (-0.97%)

BOX Box
$24.26 /

+0.15 (+0.62%)

AVCT AVCtechnologies
$5.81 /

-0.25 (-4.13%)

APOG Apogee Enterprises
$39.50 /

-1.11 (-2.73%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

ORBC Orbcomm
$7.58 /

-0.24 (-3.07%)

02/25/21 Raymond James
Orbcomm price target raised to $10 from $8 at Raymond James
02/24/21 Roth Capital
Orbcomm price target raised to $9.25 from $7.50 at Roth Capital
12/21/20 Northland
Orbcomm price target raised to $10 from $6 at Northland
07/30/20 Roth Capital
Orbcomm price target raised to $7.50 from $7 at Roth Capital
IMMP Immutep
$3.20 /

+0.17 (+5.61%)

01/26/21 Alliance Global Partners
Immutep price target raised to $6 from $5 at Alliance Global Partners
12/14/20 Maxim
Maxim doubled Immutep price target after breast cancer update
11/11/20 Maxim
Immutep price target raised to $4 from $2 at Maxim
09/22/20
Top five analyst initiations
GME GameStop
$177.95 /

-6.24 (-3.39%)

04/06/21 BofA
BofA keeps $10 target on GameStop despite 'positive' funding news
04/05/21 Telsey Advisory
Telsey keeps Underperform rating on GameStop after Q1 update, ATM program bump
03/24/21
Fly Intel: Top five analyst downgrades
03/24/21 Jefferies
GameStop price target raised to $175 from $15 at Jefferies
AVCT AVCtechnologies
$5.81 /

-0.25 (-4.13%)

04/08/21 Northland
Ribbon could see 'healthy return' on Kandy if AVC sold, says Northland
CAG Conagra Brands
$37.24 /

-0.365 (-0.97%)

01/12/21 Jefferies
Conagra Brands price target lowered to $40 from $41 at Jefferies
01/08/21 Credit Suisse
Conagra Brands price target lowered to $33 from $34 at Credit Suisse
01/05/21 Credit Suisse
Conagra Brands downgraded to Underperform from Neutral at Credit Suisse
09/29/20 RBC Capital
Conagra Brands product line benefits from current environment, says RBC Capital
APOG Apogee Enterprises
$39.50 /

-1.11 (-2.73%)

12/21/20 Craig-Hallum
Apogee Enterprises price target raised to $39 from $31 at Craig-Hallum
09/18/20 DA Davidson
Apogee Enterprises price target raised to $25 from $20 at DA Davidson
VLO Valero
$74.45 /

+0.3 (+0.40%)

04/05/21 Tudor Pickering
Valero upgraded to Buy from Hold at Tudor Pickering
04/01/21 Piper Sandler
Valero price target raised to $80 from $70 at Piper Sandler
03/08/21 Barclays
Valero price target raised to $85 from $69 at Barclays
02/26/21 Mizuho
Valero price target raised to $86 from $50 at Mizuho
BOX Box
$24.26 /

+0.15 (+0.62%)

03/23/21 KeyBanc
Box price target raised to $27 from $22 at KeyBanc
03/23/21 DA Davidson
Box price target raised to $25 from $18 at DA Davidson
01/25/21
Fly Intel: Top five analyst downgrades
01/25/21 DA Davidson
Box downgraded to Neutral from Buy at DA Davidson
OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

02/22/21 Piper Sandler
Otonomy price target lowered to $5 from $10 at Piper Sandler
12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
AMRS Amyris
$16.87 /

-1.37 (-7.51%)

03/03/21 Roth Capital
Amyris price target raised to $33 from $20 at Roth Capital
03/03/21 H.C. Wainwright
Amyris price target raised to $35 from $11 at H.C. Wainwright
02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
CGC Canopy Growth
$29.92 /

-0.97 (-3.14%)

04/08/21 Alliance Global Partners
Canopy Growth price target lowered to C$40 from C$60 at Alliance Global Partners
04/06/21 MKM Partners
Canopy Growth price target raised to C$55 from C$28 at MKM Partners
04/05/21 CIBC
Canopy Growth price target lowered to C$55 from C$64 at CIBC
03/29/21 Stifel
Stifel says New York adult use cannabis market represents $5B opportunity
VLO Valero
$74.45 /

+0.3 (+0.40%)

OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

ORBC Orbcomm
$7.58 /

-0.24 (-3.07%)

GME GameStop
$177.95 /

-6.24 (-3.39%)

CGC Canopy Growth
$29.92 /

-0.97 (-3.14%)

CAG Conagra Brands
$37.24 /

-0.365 (-0.97%)

BOX Box
$24.26 /

+0.15 (+0.62%)

APOG Apogee Enterprises
$39.50 /

-1.11 (-2.73%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

  • 09
    Apr
  • 08
    Apr
  • 09
    Jul
VLO Valero
$74.45 /

+0.3 (+0.40%)

GME GameStop
$177.95 /

-6.24 (-3.39%)

CGC Canopy Growth
$29.92 /

-0.97 (-3.14%)

CAG Conagra Brands
$37.24 /

-0.365 (-0.97%)

BOX Box
$24.26 /

+0.15 (+0.62%)

OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

IMMP Immutep
$3.20 /

+0.17 (+5.61%)

GME GameStop
$177.95 /

-6.24 (-3.39%)

CGC Canopy Growth
$29.92 /

-0.97 (-3.14%)

CAG Conagra Brands
$37.24 /

-0.365 (-0.97%)

BOX Box
$24.26 /

+0.15 (+0.62%)

AVCT AVCtechnologies
$5.81 /

-0.25 (-4.13%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

VLO Valero
$74.45 /

+0.3 (+0.40%)

GME GameStop
$177.95 /

-6.24 (-3.39%)

CGC Canopy Growth
$29.92 /

-0.97 (-3.14%)

BOX Box
$24.26 /

+0.15 (+0.62%)

AVCT AVCtechnologies
$5.81 /

-0.25 (-4.13%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

Syndicate
Otonomy 6.29M share Spot Secondary priced at $2.25 » 06:16
04/08/21
04/08
06:16
04/08/21
06:16
OTIC

Otonomy

$2.46 /

-0.11 (-4.28%)

The deal priced below the…

The deal priced below the last closing price of $2.45. Cowen and Piper Sandler are acting as joint book running managers for the offering.

ShowHide Related Items >><<
OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

02/22/21 Piper Sandler
Otonomy price target lowered to $5 from $10 at Piper Sandler
12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

  • 08
    Apr
  • 09
    Jul
OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

Wednesday
On The Fly
Fly Intel: After-Hours Movers » 18:56
04/07/21
04/07
18:56
04/07/21
18:56
RGP

Resources Connection

$13.63 /

-0.12 (-0.87%)

, AVCT

AVCtechnologies

$5.81 /

-0.25 (-4.13%)

, LNDC

Landec

$10.92 /

-0.2 (-1.80%)

, KDNY

Chinook Therapeutics

$14.77 /

-0.1 (-0.67%)

, AMRS

Amyris

$16.87 /

-1.37 (-7.51%)

, OTIC

Otonomy

$2.46 /

-0.11 (-4.28%)

, PRGS

Progress Software

$46.20 /

-0.6501 (-1.39%)

Check out this evening's…

ShowHide Related Items >><<
RGP Resources Connection
$13.63 /

-0.12 (-0.87%)

PRGS Progress Software
$46.20 /

-0.6501 (-1.39%)

OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

LNDC Landec
$10.92 /

-0.2 (-1.80%)

KDNY Chinook Therapeutics
$14.77 /

-0.1 (-0.67%)

AVCT AVCtechnologies
$5.81 /

-0.25 (-4.13%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

RGP Resources Connection
$13.63 /

-0.12 (-0.87%)

06/19/20 Sidoti
Resources Connection initiated with a Buy at Sidoti
AVCT AVCtechnologies
$5.81 /

-0.25 (-4.13%)

LNDC Landec
$10.92 /

-0.2 (-1.80%)

06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 Lake Street
Landec price target raised to $11 after revenue beat at Lake Street
06/30/20 Barrington
Landec downgraded to Market Perform from Outperform at Barrington
04/21/20 Roth Capital
Landec upgraded to Buy from Neutral at Roth Capital
KDNY Chinook Therapeutics
$14.77 /

-0.1 (-0.67%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
01/06/21
Fly Intel: Top five analyst initiations
01/06/21 Wedbush
Wedbush bullish on Chinook Therapeutics, initiates with an Outperform
AMRS Amyris
$16.87 /

-1.37 (-7.51%)

03/03/21 Roth Capital
Amyris price target raised to $33 from $20 at Roth Capital
03/03/21 H.C. Wainwright
Amyris price target raised to $35 from $11 at H.C. Wainwright
02/26/21
Fly Intel: Top five analyst initiations
02/26/21 Roth Capital
Amyris initiated with a Buy at Roth Capital
OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

02/22/21 Piper Sandler
Otonomy price target lowered to $5 from $10 at Piper Sandler
12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
PRGS Progress Software
$46.20 /

-0.6501 (-1.39%)

08/26/20 Wedbush
Progress Software assumed with an Outperform at Wedbush
06/26/20 Benchmark
Progress Software price target raised to $43 from $39 at Benchmark
RGP Resources Connection
$13.63 /

-0.12 (-0.87%)

PRGS Progress Software
$46.20 /

-0.6501 (-1.39%)

OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

LNDC Landec
$10.92 /

-0.2 (-1.80%)

KDNY Chinook Therapeutics
$14.77 /

-0.1 (-0.67%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

  • 08
    Apr
  • 09
    Jul
RGP Resources Connection
$13.63 /

-0.12 (-0.87%)

PRGS Progress Software
$46.20 /

-0.6501 (-1.39%)

OTIC Otonomy
$2.46 /

-0.11 (-4.28%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

RGP Resources Connection
$13.63 /

-0.12 (-0.87%)

PRGS Progress Software
$46.20 /

-0.6501 (-1.39%)

LNDC Landec
$10.92 /

-0.2 (-1.80%)

KDNY Chinook Therapeutics
$14.77 /

-0.1 (-0.67%)

AVCT AVCtechnologies
$5.81 /

-0.25 (-4.13%)

AMRS Amyris
$16.87 /

-1.37 (-7.51%)

Syndicate
Otonomy announces common stock offering, no amount given » 16:08
04/07/21
04/07
16:08
04/07/21
16:08
OTIC

Otonomy

$2.44 /

-0.13 (-5.06%)

Otonomy announced that it…

Otonomy announced that it has commenced an underwritten public offering of its common stock. Cowen and Piper Sandler are acting as joint book-running managers in the offering.

ShowHide Related Items >><<
OTIC Otonomy
$2.44 /

-0.13 (-5.06%)

OTIC Otonomy
$2.44 /

-0.13 (-5.06%)

02/22/21 Piper Sandler
Otonomy price target lowered to $5 from $10 at Piper Sandler
12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
OTIC Otonomy
$2.44 /

-0.13 (-5.06%)

  • 09
    Jul
OTIC Otonomy
$2.44 /

-0.13 (-5.06%)

Over a week ago
Hot Stocks
Otonomy initiates phase 2 clinical trial of OTO-313 in Tinnitus » 07:33
03/25/21
03/25
07:33
03/25/21
07:33
OTIC

Otonomy

$2.65 /

-0.11 (-3.99%)

Otonomy announced the…

Otonomy announced the initiation of a Phase 2 clinical trial of OTO-313 in patients with unilateral tinnitus. The randomized, double-blind, placebo-controlled Phase 2 study will enroll approximately 140 patients with persistent, early onset tinnitus of at least moderate severity. Following the successful Phase 1/2 trial, the primary efficacy endpoint will be a responder analysis based on the proportion of patients reporting a clinically meaningful improvement in TFI from baseline to both Month 1 and Month 2 following treatment. Top-line results are expected in mid-2022. The Phase 2 trial will be conducted at approximately 50 clinical sites in the U.S. and Europe. Following a lead-in period, patients will be randomized to a single intratympanic injection of OTO-313 or placebo and then followed for four months. In order to assess durability of the treatment benefit, patients will be followed for an additional two months. Other measures of efficacy include tinnitus loudness, tinnitus annoyance, and patient global impression of change.

ShowHide Related Items >><<
OTIC Otonomy
$2.65 /

-0.11 (-3.99%)

OTIC Otonomy
$2.65 /

-0.11 (-3.99%)

02/22/21 Piper Sandler
Otonomy price target lowered to $5 from $10 at Piper Sandler
12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
OTIC Otonomy
$2.65 /

-0.11 (-3.99%)

  • 09
    Jul
OTIC Otonomy
$2.65 /

-0.11 (-3.99%)

Over a month ago
Recommendations
Otonomy price target lowered to $5 from $10 at Piper Sandler » 11:03
02/22/21
02/22
11:03
02/22/21
11:03
OTIC

Otonomy

$3.05 /

-2.33 (-43.31%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren lowered the firm's price target on Otonomy to $5 from $10 and keeps an Overweight rating on the shares after the third Otividex Phase III trial missed the primary endpoint. While the intent-to-treat analysis fell short, management noted that the per protocol analysis reached statistics when 12 patients were excluded, so they are continuing to analyze the data to better understand why this occurred, Van Buren tells investors in a research note. The analyst says while not impossible, the precedent of achieving an approval with a non-intent-to-treat patient population is not strong. As such, he decreased the price target to $5 as a result of the "increased uncertainty."

ShowHide Related Items >><<
OTIC Otonomy
$3.05 /

-2.33 (-43.31%)

OTIC Otonomy
$3.05 /

-2.33 (-43.31%)

12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
OTIC Otonomy
$3.05 /

-2.33 (-43.31%)

  • 09
    Jul
OTIC Otonomy
$3.05 /

-2.33 (-43.31%)

On The Fly
Fly Intel: Pre-market Movers » 09:04
02/22/21
02/22
09:04
02/22/21
09:04
CTB

Cooper Tire

$43.76 /

+0.96 (+2.24%)

, PBCT

People's United

$15.68 /

+0.355 (+2.32%)

, KSS

Kohl's

$52.72 /

+4.22 (+8.70%)

, DISCA

Discovery

$50.73 /

+1.02 (+2.05%)

, GLOP

GasLog Partners

$3.37 /

+0.06 (+1.81%)

, GLOG

GasLog

$4.97 /

+0.175 (+3.65%)

, DISH

Dish

$33.67 /

-0.175 (-0.52%)

, MGI

MoneyGram

$10.85 /

-0.015 (-0.14%)

, OTIC

Otonomy

$5.38 /

+0.025 (+0.47%)

, FAII

Fortress Value Acquisition Corp. II

$12.12 /

+0.13 (+1.08%)

, RWLK

ReWalk Robotics

$4.07 /

+0.46 (+12.74%)

, EBIX

Ebix

$50.80 /

-0.7 (-1.36%)

, GT

Goodyear Tire

$13.89 /

+0.21 (+1.54%)

, MTB

M&T Bank

$149.87 /

+3.18 (+2.17%)

, BA

Boeing

$217.47 /

+9.04 (+4.34%)

, UAL

United Airlines

$48.01 /

+3.07 (+6.83%)

, RTX

Raytheon Technologies

$74.30 /

+1.45 (+1.99%)

Check out this morning's…

ShowHide Related Items >><<
UAL United Airlines
$48.01 /

+3.07 (+6.83%)

RWLK ReWalk Robotics
$4.07 /

+0.46 (+12.74%)

RTX Raytheon Technologies
$74.30 /

+1.45 (+1.99%)

PBCT People's United
$15.68 /

+0.355 (+2.32%)

OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

MTB M&T Bank
$149.87 /

+3.18 (+2.17%)

MGI MoneyGram
$10.85 /

-0.015 (-0.14%)

KSS Kohl's
$52.72 /

+4.22 (+8.70%)

GT Goodyear Tire
$13.89 /

+0.21 (+1.54%)

GLOP GasLog Partners
$3.37 /

+0.06 (+1.81%)

GLOG GasLog
$4.97 /

+0.175 (+3.65%)

FAII Fortress Value Acquisition Corp. II
$12.12 /

+0.13 (+1.08%)

EBIX Ebix
$50.80 /

-0.7 (-1.36%)

DISH Dish
$33.67 /

-0.175 (-0.52%)

DISCA Discovery
$50.73 /

+1.02 (+2.05%)

CTB Cooper Tire
$43.76 /

+0.96 (+2.24%)

BA Boeing
$217.47 /

+9.04 (+4.34%)

CTB Cooper Tire
$43.76 /

+0.96 (+2.24%)

01/13/21 Northcoast
Goodyear, Cooper to reap benefits as auto production normalizes, says Northcoast
01/08/21 KeyBanc
Cooper Tire price target raised to $50 from $48 at KeyBanc
10/22/20 JPMorgan
Cooper Tire price target raised to $42 from $39 at JPMorgan
07/14/20 KeyBanc
Tire data for June supportive of upside, says KeyBanc
PBCT People's United
$15.68 /

+0.355 (+2.32%)

01/25/21 Deutsche Bank
People's United price target raised to $15 from $13 at Deutsche Bank
01/07/21 Jefferies
People's United upgraded to Buy with $16 price target at Jefferies
01/07/21 Jefferies
People's United upgraded to Buy from Hold at Jefferies
12/17/20 Seaport Global
Seaport Global rolls out coverage of Regional and Community Banks with 4 Buys
KSS Kohl's
$52.72 /

+4.22 (+8.70%)

02/18/21 Morgan Stanley
Kohl's price target raised to $40 from $27 at Morgan Stanley
02/05/21 Baird
Kohl's price target raised to $58 from $48 at Baird
02/05/21 Deutsche Bank
Kohl's price target raised to $55 from $51 at Deutsche Bank
02/03/21
Fly Intel: Top five analyst upgrades
DISCA Discovery
$50.73 /

+1.02 (+2.05%)

02/08/21 Morgan Stanley
Fox Corp. target raised to $36 at Morgan Stanley after hypothetical LBO exercise
02/01/21 Citi
Discovery downgraded to Neutral from Buy at Citi
01/28/21 Macquarie
Discovery price target raised to $40 from $30 at Macquarie
01/19/21
Fly Intel: Top five analyst downgrades
GLOP GasLog Partners
$3.37 /

+0.06 (+1.81%)

01/29/21 Jefferies
GasLog Partners price target raised to $4 from $3.25 at Jefferies
11/11/20 B. Riley
GasLog Partners price target lowered to $3.25 from $4.50 at B. Riley Securities
04/30/20 BTIG
GasLog Partners cut to Neutral at BTIG on valuation
04/30/20 BTIG
GasLog Partners downgraded to Neutral from Buy at BTIG
GLOG GasLog
$4.97 /

+0.175 (+3.65%)

01/29/21 Jefferies
GasLog price target raised to $5.50 from $4.50 at Jefferies
01/27/21 Evercore ISI
GasLog downgraded to In Line from Outperform at Evercore ISI
01/27/21 Evercore ISI
GasLog downgraded to In Line from Outperform at Evercore ISI
09/01/20 DNB Markets
GasLog upgraded to Buy from Hold at DNB Markets
DISH Dish
$33.67 /

-0.175 (-0.52%)

12/04/20 Guggenheim
Dish downgraded to Neutral from Buy at Guggenheim
11/18/20 Deutsche Bank
Dish price target lowered to $65 from $69 at Deutsche Bank
11/12/20 Raymond James
Dish price target raised to $58 from $50 at Raymond James
07/20/20 Credit Suisse
F5 Networks price target raised to $170 from $151 at Credit Suisse
MGI MoneyGram
$10.85 /

-0.015 (-0.14%)

01/19/21 DA Davidson
DA Davidson doesn't see Walmart adding Western Union to hurt Euronet materially
01/11/21 Northland
MoneyGram upgraded to Outperform from Market Perform at Northland
08/03/20 Evercore ISI
MoneyGram upgraded to In Line from Underperform at Evercore ISI
06/10/20
Fly Intel: Top five analyst downgrades
OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
FAII Fortress Value Acquisition Corp. II
$12.12 /

+0.13 (+1.08%)

RWLK ReWalk Robotics
$4.07 /

+0.46 (+12.74%)

EBIX Ebix
$50.80 /

-0.7 (-1.36%)

05/12/20 Craig-Hallum
Ebix shares and estimates 'have put in a floor,' says Craig-Hallum
05/12/20 BMO Capital
Ebix price target lowered to $34 from $43 at BMO Capital
04/30/20 Craig-Hallum
Ebix price target lowered to $75 from $80 at Craig-Hallum
03/26/20 Craig-Hallum
Ebix to be top performer as investors realize stock mispriced, says Craig-Hallum
GT Goodyear Tire
$13.89 /

+0.21 (+1.54%)

02/16/21 Argus
Goodyear Tire upgraded to Buy from Hold at Argus
02/16/21 Argus
Goodyear Tire upgraded to Buy from Hold at Argus
02/10/21 Northcoast
Goodyear Tire price target raised to $15 from $12 at Northcoast
02/10/21
Fly Intel: Top five analyst upgrades
MTB M&T Bank
$149.87 /

+3.18 (+2.17%)

02/17/21 Citi
Citi recommends two new U.S. bank pair trades
01/28/21 Deutsche Bank
M&T Bank price target raised to $161 from $155 at Deutsche Bank
01/22/21 RBC Capital
M&T Bank price target raised to $150 from $130 at RBC Capital
01/07/21 BofA
M&T Bank upgraded to Buy from Neutral at BofA
BA Boeing
$217.47 /

+9.04 (+4.34%)

02/19/21 Benchmark
Boeing price target lowered to $270 from $290 at Benchmark
02/10/21 Deutsche Bank
Airbus initiated with a Buy at Deutsche Bank
01/29/21
Fly Intel: Top five analyst upgrades Spire
01/29/21 Morgan Stanley
Morgan Stanley double upgrades Boeing to Overweight after 'kitchen sink' Q4
UAL United Airlines
$48.01 /

+3.07 (+6.83%)

02/22/21 Deutsche Bank
Deutsche upgrades eight airlines with Covid trending in right direction
02/22/21 Deutsche Bank
United Airlines upgraded to Buy from Hold at Deutsche Bank
02/17/21 BofA
Mesa Air double-upgraded to Buy from Underperform at BofA
02/10/21 JPMorgan
JPMorgan sees less than 15% chance of pre-flight COVID-19 testing
RTX Raytheon Technologies
$74.30 /

+1.45 (+1.99%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
12/21/20 Canaccord
Boeing not in position to challenge Aerojet bid, says Canaccord
12/21/20 RBC Capital
Aerojet Rocketdyne price target raised to $56 from $51 at RBC Capital
12/17/20 DZ Bank
Raytheon Technologies upgraded to Buy from Hold at DZ Bank
UAL United Airlines
$48.01 /

+3.07 (+6.83%)

RWLK ReWalk Robotics
$4.07 /

+0.46 (+12.74%)

RTX Raytheon Technologies
$74.30 /

+1.45 (+1.99%)

PBCT People's United
$15.68 /

+0.355 (+2.32%)

OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

MTB M&T Bank
$149.87 /

+3.18 (+2.17%)

MGI MoneyGram
$10.85 /

-0.015 (-0.14%)

KSS Kohl's
$52.72 /

+4.22 (+8.70%)

GT Goodyear Tire
$13.89 /

+0.21 (+1.54%)

GLOP GasLog Partners
$3.37 /

+0.06 (+1.81%)

GLOG GasLog
$4.97 /

+0.175 (+3.65%)

EBIX Ebix
$50.80 /

-0.7 (-1.36%)

DISH Dish
$33.67 /

-0.175 (-0.52%)

DISCA Discovery
$50.73 /

+1.02 (+2.05%)

CTB Cooper Tire
$43.76 /

+0.96 (+2.24%)

BA Boeing
$217.47 /

+9.04 (+4.34%)

  • 09
    Jul
  • 22
    Apr
UAL United Airlines
$48.01 /

+3.07 (+6.83%)

RTX Raytheon Technologies
$74.30 /

+1.45 (+1.99%)

PBCT People's United
$15.68 /

+0.355 (+2.32%)

MGI MoneyGram
$10.85 /

-0.015 (-0.14%)

KSS Kohl's
$52.72 /

+4.22 (+8.70%)

DISH Dish
$33.67 /

-0.175 (-0.52%)

DISCA Discovery
$50.73 /

+1.02 (+2.05%)

BA Boeing
$217.47 /

+9.04 (+4.34%)

UAL United Airlines
$48.01 /

+3.07 (+6.83%)

RTX Raytheon Technologies
$74.30 /

+1.45 (+1.99%)

OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

MGI MoneyGram
$10.85 /

-0.015 (-0.14%)

KSS Kohl's
$52.72 /

+4.22 (+8.70%)

GT Goodyear Tire
$13.89 /

+0.21 (+1.54%)

DISH Dish
$33.67 /

-0.175 (-0.52%)

DISCA Discovery
$50.73 /

+1.02 (+2.05%)

BA Boeing
$217.47 /

+9.04 (+4.34%)

UAL United Airlines
$48.01 /

+3.07 (+6.83%)

RWLK ReWalk Robotics
$4.07 /

+0.46 (+12.74%)

RTX Raytheon Technologies
$74.30 /

+1.45 (+1.99%)

MGI MoneyGram
$10.85 /

-0.015 (-0.14%)

KSS Kohl's
$52.72 /

+4.22 (+8.70%)

GT Goodyear Tire
$13.89 /

+0.21 (+1.54%)

DISH Dish
$33.67 /

-0.175 (-0.52%)

DISCA Discovery
$50.73 /

+1.02 (+2.05%)

BA Boeing
$217.47 /

+9.04 (+4.34%)

Hot Stocks
Otonomy says Phase 3 trial of OTIVIDEX did not meet primary endpoint » 07:08
02/22/21
02/22
07:08
02/22/21
07:08
OTIC

Otonomy

$5.38 /

+0.025 (+0.47%)

Otonomy announced that…

Otonomy announced that the Phase 3 clinical trial of OTIVIDEX in patients with Meniere's disease did not achieve the primary endpoint, which was the count of definitive vertigo days in Month 3 for OTIVIDEX vs. placebo for the intent-to-treat population using the Negative Binomial Model. This analysis did achieve statistical significance for the per protocol population. These results were similar using the Generalized Poisson model. "We are disappointed by the top-line results for the primary intent-to-treat population and are undertaking an assessment to understand the difference observed with the per protocol analysis. We thank the many patients, clinical investigators and study site staff who supported this effort," said David Weber, Ph.D., president and CEO of Otonomy. "Our focus turns to the strong pipeline we have built as recently highlighted by the successful clinical trial results for OTO-313 in tinnitus and OTO-413 in hearing loss. OTO-313 and OTO-413 each address a large patient population with significant unmet need and no approved drug therapy. These programs provide an attractive opportunity for the company with clinical readouts anticipated in mid-2022. We expect that our existing cash balance will permit us to achieve these clinical readouts as well as advance our preclinical hearing loss programs including OTO-825, a gene therapy for congenital hearing loss." The company previously reported a cash balance including cash, cash equivalents, and short-term investments totaling $86.3M as of December 31, 2020, GAAP operating expenses for full year 2020 of $42.6M and non-GAAP operating expenses, which exclude stock-based compensation, for full year 2020 of $36.5M.

ShowHide Related Items >><<
OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

  • 09
    Jul
OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

Hot Stocks
Otonomy trading halted, news pending  06:55
02/22/21
02/22
06:55
02/22/21
06:55
OTIC

Otonomy

$5.38 /

+0.025 (+0.47%)

 
ShowHide Related Items >><<
OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

  • 09
    Jul
OTIC Otonomy
$5.38 /

+0.025 (+0.47%)

Earnings
Otonomy reports Q4 EPS (20c), consensus (22c) » 16:34
02/11/21
02/11
16:34
02/11/21
16:34
OTIC

Otonomy

$5.35 /

+ (+0.00%)

Cash, cash equivalents,…

Cash, cash equivalents, and short-term investments totaled $86.3 million as of December 31, 2020, compared to $60.7 million as of December 31, 2019. In July 2020, Otonomy completed an underwritten public offering of 17,275,000 shares of its common stock, which includes the underwriters' full exercise of their option to purchase additional shares, and the Company sold pre-funded warrants to purchase up to 4,000,000 shares of its common stock, for total gross proceeds of approximately $69.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by Otonomy. All of the securities were sold by Otonomy. ."We made great progress in advancing our product pipeline and achieving our corporate objectives during 2020 including positive clinical results for OTO-313 in tinnitus, positive clinical results for OTO-413 in hearing loss, and completion of enrollment for our Phase 3 trial of OTIVIDEX in Meniere's disease," said David A. Weber, Ph.D., president and CEO of Otonomy. "We also selected a product candidate, OTO-825, for our GJB2 gene therapy program, demonstrated preclinical proof-of-concept for our otoprotection program, and licensed a novel compound for our OTO-6XX hair cell repair and regeneration program. We are looking forward to important catalysts this year beginning with the OTIVIDEX Phase 3 results later this month."

ShowHide Related Items >><<
OTIC Otonomy
$5.35 /

+ (+0.00%)

OTIC Otonomy
$5.35 /

+ (+0.00%)

12/18/20 H.C. Wainwright
Otonomy price target raised to $10 from $9 at H.C. Wainwright
12/17/20 Piper Sandler
Piper says Otonomy's OTO-413 appears active, peak sales 'not accounted for'
11/04/20 Piper Sandler
Piper Sandler likes risk/reward on Otonomy ahead of two readouts by year-end
07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
OTIC Otonomy
$5.35 /

+ (+0.00%)

  • 09
    Jul
OTIC Otonomy
$5.35 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.